Production (Stage)
Adaptimmune Therapeutics plc
ADAP
$0.2801
$0.00572.08%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -69.90M | -70.81M | -44.52M | -72.50M | -163.41M |
| Total Depreciation and Amortization | 10.86M | 11.23M | 11.26M | 11.34M | 10.83M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 19.87M | 23.36M | 13.82M | 10.19M | -11.02M |
| Change in Net Operating Assets | -68.69M | -36.98M | -34.25M | 6.59M | 28.06M |
| Cash from Operations | -107.85M | -73.21M | -53.68M | -44.39M | -135.55M |
| Capital Expenditure | -1.99M | -886.00K | -1.49M | -1.64M | -2.43M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | 0.00 | 0.00 | 45.26M |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -15.45M | -58.07M | 2.57M | 126.04M | 85.01M |
| Cash from Investing | -17.44M | -58.95M | 1.08M | 124.40M | 127.84M |
| Total Debt Issued | 49.50M | 49.50M | 49.50M | 24.50M | -- |
| Total Debt Repaid | -25.45M | -- | -- | -- | -- |
| Issuance of Common Stock | 145.00K | 29.25M | 29.32M | 29.92M | 29.92M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 24.19M | 78.75M | 78.82M | 54.42M | 29.92M |
| Foreign Exchange rate Adjustments | 570.00K | -402.00K | 128.00K | 43.00K | -127.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -100.52M | -53.81M | 26.35M | 134.48M | 22.08M |